224 related articles for article (PubMed ID: 24751453)
1. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Sweiss NJ; Noth I; Mirsaeidi M; Zhang W; Naureckas ET; Hogarth DK; Strek M; Caligiuri P; Machado RF; Niewold TB; Garcia JG; Pangan AL; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):46-54. PubMed ID: 24751453
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.
Sweiss NJ; Barnathan ES; Lo K; Judson MA; Baughman R;
Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(1):49-56. PubMed ID: 21086905
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.
Erckens RJ; Mostard RL; Wijnen PA; Schouten JS; Drent M
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):713-20. PubMed ID: 22119879
[TBL] [Abstract][Full Text] [Related]
4. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
Baughman RP; Drent M; Kavuru M; Judson MA; Costabel U; du Bois R; Albera C; Brutsche M; Davis G; Donohue JF; Müller-Quernheim J; Schlenker-Herceg R; Flavin S; Lo KH; Oemar B; Barnathan ES;
Am J Respir Crit Care Med; 2006 Oct; 174(7):795-802. PubMed ID: 16840744
[TBL] [Abstract][Full Text] [Related]
5. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Russell E; Luk F; Manocha S; Ho T; O'Connor C; Hussain H
Semin Arthritis Rheum; 2013 Aug; 43(1):119-24. PubMed ID: 23332903
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for refractory pulmonary sarcoidosis.
Minnis PA; Poland M; Keane MP; Donnelly SC
Ir J Med Sci; 2016 Nov; 185(4):969-971. PubMed ID: 26428728
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.
Vorselaars AD; Crommelin HA; Deneer VH; Meek B; Claessen AM; Keijsers RG; van Moorsel CH; Grutters JC
Eur Respir J; 2015 Jul; 46(1):175-85. PubMed ID: 25929955
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study.
Goljan-Geremek A; Bednarek M; Franczuk M; Puścińska E; Nowiński A; Czystowska M; Kamiński D; Korzybski D; Stokłosa A; Kowalska A; Wojda E; Sliwiński P; Burakowska B; Ptak J; Barańska I; Drygalska A; Małek G; Bestry I; Wesołowski S; Kram M; Górecka D
Pneumonol Alergol Pol; 2014; 82(6):518-33. PubMed ID: 25339562
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
[TBL] [Abstract][Full Text] [Related]
12. Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis.
Drake WP; Culver DA; Baughman RP; Judson MA; Crouser ED; James WE; Ayers GD; Ding T; Abel K; Green A; Kerrigan A; Sesay A; Bernard GR
Chest; 2021 May; 159(5):1902-1912. PubMed ID: 33387486
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
[TBL] [Abstract][Full Text] [Related]
14. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
Afif W; Leighton JA; Hanauer SB; Loftus EV; Faubion WA; Pardi DS; Tremaine WJ; Kane SV; Bruining DH; Cohen RD; Rubin DT; Hanson KA; Sandborn WJ
Inflamm Bowel Dis; 2009 Sep; 15(9):1302-7. PubMed ID: 19408340
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
16. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis.
Rezaee M; Zangiabadian M; Soheili A; Calcagno TM; Rahmannia M; Dinparastisaleh R; Nasiri MJ; Mirsaeidi M
Eur J Intern Med; 2023 Mar; 109():42-49. PubMed ID: 36526497
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
[TBL] [Abstract][Full Text] [Related]
18. Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis.
Alhamad EH; Shaik SA; Idrees MM; Alanezi MO; Isnani AC
BMC Pulm Med; 2010 Aug; 10():42. PubMed ID: 20696064
[TBL] [Abstract][Full Text] [Related]
19. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial.
Judson MA; Baughman RP; Costabel U; Mack M; Barnathan ES
Respir Med; 2014 Jan; 108(1):189-94. PubMed ID: 24361164
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
